<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312880</url>
  </required_header>
  <id_info>
    <org_study_id>5176</org_study_id>
    <nct_id>NCT04312880</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Infusion During Elective Spine Surgery</brief_title>
  <official_title>Tranexamic Acid Infusion During Elective Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid (TXA) is an agent that has been shown to be safe and effective to reduce&#xD;
      blood loss in surgical procedures. The purpose of the study is to assess the effect of&#xD;
      transexamic on elective decompressive lumbar spine surgery with and without fusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective randomized control, double-blinded investigation. The&#xD;
      Investigators will recruit patients undergoing elective, primary, decompressive lumbar&#xD;
      surgery via a posterior surgical approach of less than 3 levels. This includes patients&#xD;
      undergoing decompressive lumbar laminectomies with or without fusion. Fusion may include&#xD;
      posterior interbody and/or posterior lateral techniques with instrumentation.&#xD;
&#xD;
      There will be 3 treatment arms with the goal of 65 patients in each arm. Patients will be&#xD;
      randomized pre-operatively and enrolled into the IV transexamic acid group (receiving&#xD;
      intraoperative intravenous tranexamic acid infusion), or the topical transexamic acid group&#xD;
      or the control/placebo group (receiving intraoperative intravenous saline). The Investigators&#xD;
      expect the duration of each treatment group to be approximately 4-5 months. Therefore, the&#xD;
      study should be completed within 1.5 years. The primary surgeon and anesthesia staff will not&#xD;
      be blinded to the treatment arm due to the nature of the different administration routes, but&#xD;
      post-operative nursing staff will be blinded to administration routes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drain output</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Drains will be placed during surgery, this will be recorded by nursing staff on a regular schedule and we will assess the results as a surrogate for blood loss post operatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hematocrit</measure>
    <time_frame>two days post operatively</time_frame>
    <description>Labs will be recorded each morning after the surgery, this includes hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>two days post operatively</time_frame>
    <description>Labs will be recorded each morning after the surgery, this includes hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency department visits</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>We will assess which treatment arms, if any had increased rate of Emergency department visits for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospital readmissions</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>We will assess which treatment arms, if any had increased rate of readmission to the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of PE</measure>
    <time_frame>30 days post opertively</time_frame>
    <description>We will assess is any treatment arm had an increased risk of PE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of DVT</measure>
    <time_frame>30 days post opertively</time_frame>
    <description>We will assess is any treatment arm had an increased risk of DVT</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Spine Surgery</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will receive no transexemic acid of any kind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV-transexemic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weight adjusted standard dose of TXA will be administered to these subset of patients prior to incision in IV-form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical-transexemic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the wound site after the surgery is completed will be bathed in TXA for a standardized period of time prior to skin closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>IV and topical form of TXA will be administered to patients in the respective groups.</description>
    <arm_group_label>IV-transexemic acid</arm_group_label>
    <arm_group_label>Topical-transexemic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing decompressive lumbar laminectomy with or without fusion&#xD;
&#xD;
          -  Primary surgical procedure&#xD;
&#xD;
          -  Competent adult able to give informed consent&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  h/o DVT or PE&#xD;
&#xD;
          -  h/o seizure&#xD;
&#xD;
          -  h/o coagulopathy&#xD;
&#xD;
          -  Diagnosis of malignancy or infection as indication for surgical decompression&#xD;
&#xD;
          -  Abnormal pre-operative PT/INR, aPTT, bleeding time&#xD;
&#xD;
          -  Platelet count &lt; 100&#xD;
&#xD;
          -  Patients requiring therapeutic heparin or lovenox bridges prior to and/or after&#xD;
             surgery&#xD;
&#xD;
          -  Allergy to TXA&#xD;
&#xD;
          -  Pregnant women and prisoners&#xD;
&#xD;
          -  Renal insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Lawrence, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending Surgeon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

